Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Abrocitinib Formulations in Healthy Participants
NCT04065633Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abrocitinib in atopic dermatitis (AD) (4 arms), sponsored by Pfizer. Primary endpoint: Plasma PF-04965842 PK parameters at 48 hours. Started Jul 2019; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04065633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065633.